Jain, L., Chain, A. S., Tatosian, D. A., Hing, J., Passarell, J. A., Kauh, E. A., & Lai, E. (2019). Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin. Br J Clin Pharmacol.

Jain, Lokesh, Anne S.Y Chain, Daniel A. Tatosian, Jeremy Hing, Julie A. Passarell, Eunkyung A. Kauh, et Eseng Lai. "Pharmacokinetic–pharmacodynamic (dipeptidyl Peptidase‐4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those With Renal Impairment, for Once‐weekly Administered Omarigliptin." Br J Clin Pharmacol 2019.

Jain, Lokesh, et al. "Pharmacokinetic–pharmacodynamic (dipeptidyl Peptidase‐4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those With Renal Impairment, for Once‐weekly Administered Omarigliptin." Br J Clin Pharmacol 2019.